US prices of some psoriasis drugs need to be lowered to match benefits, new study says
The prices of drugs for psoriasis need to be reduced by about 71% to match their efficacy, researchers from Harvard Medical School and the Brigham and Women’s Hospital said in a study published in JAMA Dermatology on Wednesday.
The researchers looked at the net prices of 11 biologics and two biosimilars for psoriasis, which ranged from $1,664 to $79,277 per year, finding that efficacy in the clinic didn’t match some of the high prices, according to the study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
